Epstein–Barr virus-associated B cell lymphoproliferative disease after non-myeloablative allogeneic stem cell transplantation
Open Access
- 1 March 1999
- journal article
- case report
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 23 (6) , 629-630
- https://doi.org/10.1038/sj.bmt.1701628
Abstract
There is a growing interest in the evaluation of non-myeloablative conditioning therapy for allogeneic stem cell transplantation. Such regimens are expected to produce less toxicity while allowing both engraftment and a graft-versus-disease effect from the large number of donor-derived immunocompetent T lymphocytes given with the stem cells. Heavy immunosuppression used in recipients may have unexpected consequences. We describe the occurrence of a fatal Epstein–Barr virus-associated B cell lymphoproliferative disease (BLPD) early after such a non-myeloablated allogeneic peripheral blood stem cell transplant in a heavily pre-treated patient.Keywords
This publication has 0 references indexed in Scilit: